Influence of treatment with 3′-deoxyadenosine associated deoxycoformycin on hematological parameters and activity of adenosine deaminase in infected mice with Trypanosoma evansi  by Dalla Rosa, Luciana et al.
Experimental Parasitology 135 (2013) 357–362Contents lists available at ScienceDirect
Experimental Parasitology
journal homepage: www.elsevier .com/locate /yexprInﬂuence of treatment with 30-deoxyadenosine associated
deoxycoformycin on hematological parameters and activity
of adenosine deaminase in infected mice with Trypanosoma evansi0014-4894/$ - see front matter  2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.exppara.2013.07.019
⇑ Corresponding author at: Departamento de Microbiologia e Parasitologia, Universidade Federal de Santa Maria, Av. Roraima no 1000, Camobi, Santa Maria, RS, CE
900, Brazil. Fax: +55 55 3220 8242.
E-mail addresses: lucianadallarosa@gmail.com, ludallarosa@hotmail.com (L. Dalla Rosa).Luciana Dalla Rosa a,⇑, Aleksandro S. Da Silva b, Jader B. Ruchel a, Lucas T. Gressler a, Camila B. Oliveira a,
Raqueli T. França c, Sonia T.A. Lopes c, Daniela B.R. Leal a, Silvia G. Monteiro a
aDepartamento de Microbiologia e Parasitologia, Universidade Federal de Santa Maria, Brazil
bDepartamento de Ciência Animal, Universidade do Estado de Santa Catarina, Chapecó, Brazil
cDepartamento de Pequenos Animais, Universidade Federal de Santa Maria, Brazilh i g h l i g h t s
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caused no alterations in
hematological parameters.
 The plasma total protein levels can be
reduced as a consequence of this
treatment.
 The activity of ADA had inhibition in
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 The activity of ADA had inhibition in
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This study aimed to verify the effect of 30-deoxyadenosine and deoxycoformycin on hematologic param-
eters and adenosine deaminase (ADA) activity in plasma and brain of mice infected with Trypanosoma
evansi. Seventy animals were divided into seven groups, which were divided into two subgroups each
for sampling on days 4 and 8 post-infection (PI). The groups were composed of three uninfected groups
(A–C), namely, not-treated (A), treated with 30-deoxyadenosine (B), and treated with deoxycoformycin
(C) and four infected groups, mice with T. evansi (D–G), namely, not-treated (D), treated with 30-deoxy-
adenosine (E), treated with deoxycoformycin (F), and treated with a combination 30-deoxyadenosine and
deoxycoformycin (G). Hematological parameters and ADA activity were evaluated in plasma and brain.
Animals in groups B and C exhibited a reduction in the levels of plasma total protein compared group
A. Animals in groups D and F showed changes in the hematological parameters. The ADA activity signif-
icantly reduced in the animals of groups C, D, F and G. Mice in the group E presented increased ADA
activity in plasma. Therefore, we conclude that the treatment interferes signiﬁcantly in the hematologic
parameters in mice infected with T. evansi. On the other hand, when the ADA inhibitor was used weP 97105-
358 L. Dalla Rosa et al. / Experimental Parasitology 135 (2013) 357–362observed a signiﬁcant decrease in the values of hematocrit, total erythrocytes, and hemoglobin
concentration. The deoxycoformycin was able to inhibit the ADA activity of parasite thus it may be
one of the mechanisms of efﬁcacy of this treatment.
 2013 Elsevier Inc. All rights reserved.1. Introduction that ADA deﬁciency leads to a severe combined immunodeﬁciencyThe Trypanosoma evansi is the etiologic agent of trypanosomo-
sis, a disease with broad distribution in Africa, Asia, and Latin
America (Lun and Desser, 1995) which may result in immeasurable
economic losses (Luckins and Dwinger, 2004; Dobson et al., 2009).
The parasite is transmitted mechanically by blood-sucking insects
during feeding such as Tabanus spp. and Stomoxys spp. and/or vam-
pire bats (Hoare, 1972). A large number of species may be parasit-
ized by T. evansi including horses (in which the disease is called
‘‘Mal das cadeiras’’ or ‘‘Surra’’), camels, dogs, and in rare cases, hu-
mans (Powar et al., 2006). Trypanosome-infected animals present
clinical signs such as fever, poor body condition, weakness, subcu-
taneous edema, petechiae of the serous membranes, and instability
of the hind limbs (Silva et al., 1995). An accurate diagnosis of this
disease is possible during its acute and chronic stage, but chronic
clinical signs are more evident and the animal condition is more
severely affected (Silva et al., 2002).
In Brazil, the therapy for trypanosomosis relies on the use of
diminazene aceturate, which is effective for the treatment in cattle,
buffalo, sheep, pigs and camels (Peregrine and Mamman, 1993; Sir-
ivan et al., 1994). However, when only one dose is used the treat-
ment is not effective for horses, mules or dogs (Tuntasuvan et al.,
2003; Colpo et al., 2005), which results in lack of efﬁcacy of this
drug as a consequence (Tuntasuvan et al., 2003; Da Silva et al.,
2008). Thus, it is important to investigate alternatives to improve
the success of the treatment using new drugs, anti-protozoa asso-
ciations, and other components that could increase the curative
efﬁcacy as occurred when diminazene aceturate is associated with
selenium in the therapy of infected rats with T. evansi (Tonin et al.,
2011). Based on this idea, some studies have emerged suggesting
new options for the treatment of trypanosomosis.
The effective treatment in the cure of infected mice with Try-
panosoma brucei was observed when an analogue product of pur-
ine, 3-deoxyadenosine was used (Rottenberg et al., 2005;
Vodnala et al., 2008, 2009). The efﬁcacy of the treatment is related
to the protection of 3-deoxyadenosine against the enzyme adeno-
sine deaminase (ADA), which is responsible for the deamination of
this adenosine analogue (Rottenberg et al., 2005; Vodnala et al.,
2008, 2009). However, the administration of 3-deoxyadenosine
alone did not result in a complete cure from the infection (Aiyedun
et al., 1973; Da Silva et al., 2011d). Therefore, this treatment re-
quires the combination of 3-deoxyadenosine with an inhibitor of
ADA1 and ADA2, known as deoxycoformycin (Rottenberg et al.,
2005).
In addition to the treatment of trypanosomosis, 3-deoxyadeno-
sine combination with deoxycoformycin has been used for the
treatment of certain malignant tumors in humans, e.g., leukemia
and melanoma (Adamson et al., 1977). This adenosine analogue
can perform similar functions to adenosine that is present in all tis-
sues of mammals, demonstrating important functions related to
cell signaling, neuroprotection, thromboregulation, and immune
processes (Burnstock, 2006; Desrosiers et al., 2007). In addition,
adenosine has an anti-inﬂammatory action playing a central role
in inﬂammation and immunomodulation (Di Virgilio et al., 1998;
Luttikhuizen et al., 2004). The concentration of extracellular aden-
osine is regulated by the ADA activity, which is considered an en-
zyme in the purine metabolism, catalyzing the irreversible
deamination of adenosine and deoxyadenosine to inosine and
deoxyinosine, respectively (Franco et al., 1997). The observationsyndrome points to the physiological importance of controlling
extracellular adenosine levels (Aldrich et al., 2000).
A recent study showed that the combination of 30-deoxyadeno-
sine with deoxycoformycin was effective in treating mice infected
with T. evansi, but the cured animals showed histological lesions in
their liver and kidneys (Dalla Rosa et al., 2013). Thus, this study has
as objective to verify the effect of 30-deoxyadenosine and deoxyco-
formycin on hematologic parameters and ADA activity in plasma
and brain of mice infected with T. evansi and to check the effect
of deoxycoformycin on the ADA activity of parasite.2. Materials and methods
2.1. Drugs
30-Deoxyadenosine (Cordycepin) was obtained from Sigma
Chemical Co (St. Louis, MO, USA). Deoxycoformycin (Pentostatin)
was obtained from Tocris Bioscience (Minneapolis, MN, USA). Un-
less otherwise indicated, all reagents were diluted in PBS, aliquoted
and stored at 20 C until further use.
2.2. T. evansi isolate
To reactivate the isolated and obtain a large amount of blood
parasites for the subsequent infection of mice that formed the
experimental groups, in this study, two Wistar rats (R1 and R2)
were intraperitoneally infected with blood cryopreserved in liquid
nitrogen containing 1.3  106 trypanosomes.
2.3. Animal groups and T. evansi infection
Seventy adult female mice with a mean age of 60 days and
weighing average 23.2 ± 1.9 g were used in this study. The animals
were housed in cages, ten in each cage, in a room with controlled
temperature and humidity (25 C; 70%) on a 12 h light/dark cycle
with free access to food and water. All animals were submitted
to an adaptation period of 15 days before the beginning of the
experimental period.
Mice were divided into seven groups (A, B, C, D, E, F and G) with
10 animals each. The groups A, B and C were formed by uninfected
animals with the parasite. Animals of groups D–G were intraperi-
toneally infected with 0.1 mL of blood from rat (R1) containing
1.1  106 trypanosomes (Day 0). Subsequently, the parasitemia
was estimated daily by microscopic examination of smears. Each
slide was mounted with blood collected from the tail vein, Roma-
nowsky stain, and visualized at a magniﬁcation of 1000.
2.4. Experimental design
Group A was composed of uninfected and untreated animals
(negative control), group B consisted of uninfected and treated
with 1 mg/kg/day of 30-deoxyadenosine and the animals of group
C were uninfected and treated with 1 mg/kg/day of deoxycoformy-
cin. Group D was composed of infected and untreated animals
(positive control). Animals of groups E, F and G were infected with
T. evansi and treated with 1 mg/kg/day of 30-deoxyadenosine,
1 mg/kg/day of deoxycoformycin and treated with combina-
tion 1 mg/kg/day of 30-deoxyadenosine with 1 mg/kg/day of
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G) began 2 h after infection by the parasite and lasted for 3 days,
i.e., three doses at intervals of 24 h by intraperitoneal.
2.5. Collection of samples
The groups (n = 10) were divided into two subgroups (n = 5)
according to the date of sample collection (day 4 post-infection –
A1, B1, C1, D1, E1, F1 and G1; day 8 post-infection – A2, B2, C2,
D2, E2, F2 and G2). On days 4 and 8 post-infection (PI), the animals
were anesthetized in a chamber with isoﬂurane for collection of
blood by cardiac puncture. The material collected was allocated
in tubes with anticoagulant (ethylene-diaminetetraacetic acid-
EDTA) to evaluate the inﬂuence of treatment on hematologic
parameters and ADA activity in plasma. Thereafter, animals were
decapitated following recommendations of the Ethics Committee
and the brain was removed to evaluate the inﬂuence of the treat-
ment on the ADA activity of this tissue.
2.6. Hematological parameters
Erythrocyte count, hematocrit, hemoglobin concentration, total
leukocytes, and plasma total protein were evaluated. Erythrocytes
and total leukocytes were performed using an automated cell
counter Mindray BC-2800 Auto Hematology Veterinary Blood Ana-
lyzer. The hematocrit was obtained by centrifugation using a
microcentrifuge (Sigma) at 19,720g/5 min according to Thrall
et al. (2004).
2.7. ADA activity
2.7.1. ADA activity in plasma
ADA activity was measured spectrophotometrically in plasma
by the method of Giusti and Galanti (1984). The reaction was
started by the addition of the substrate (adenosine) to a ﬁnal con-
centration of 21 mmol/L and incubation carried out for 1 h at 37 C.
The reaction was stopped by adding 106 mmol/L/0.16 mmol/L
phenol–nitroprusside/mL solution. The reaction mixtures were
immediately mixed to 125 mmol/L/11 mmol/L alkalinehypochlo-
rite (sodium hypochlorite) and vortexed. Ammonium sulfate
75 lMwas used as ammonium standard. The ammonia concentra-
tion was directly proportional to the absorption of indophenol at
620 nm. The speciﬁc activity is reported as U/L in plasma.
2.7.2. ADA activity in brain
First, the brain was weighed, homogenized in 10 volume of
50 mmol/L per mM phosphate buffer (pH 6.5), and centrifuged
for 30 min at 14,000g at 4 C. The supernatant was then collectedTable 1
Mean and standard deviation of hematologic parameters (hematocrit, total erythrocytes,
uninfected/infected with Trypanosoma evansi and untreated/treated with 30-deoxyadenosin
Parameters Day Group A Group B Grou
Hematocrit (%) 04 45.8a (±2.4) 44.2a (±2.5) 45.5a
08 44.7ab (±2.6) 45.3ab (±1.5) 46.3a
Erythrocytes (106 lL) 04 6.7ª (±1.0) 8.0a (±0.1) 8.2ª
08 7.9ab (±0.9) 8.1abc (±0.1) 8.3ab
Hemoglobin (g/dL) 04 12.0a (±2.0) 12.7a (±0.5) 12.8a
08 12.0ab (±2.1) 12.6ab (±0.6) 12.6a
Plasma total protein (g/dL) 04 7.5a (±0.3) 6.8c (±0.3) 6.9bc
08 7.6abc (±0.1) 7.0c (±0.0) 6.9c
Leukocytes (103/lL) 04 4.2b (±1.7) 5.4ab (±1.3) 4.8b
08 4.6b (±2.1) 4.8b (±0.6) 3.9b
Same letters in the same row are not statistically different from each other, the signiﬁcan
uninfected and treated with 30-deoxyadenosine, group C: uninfected and treated with de
30-deoxyadenosine, group F: infected and treated with deoxycoformycin, and group G: ias described by Bellé et al. (2009). ADA activities were estimated
spectrophotometrically by the method of Giusti and Galanti
(1984), which is based on the direct measurement of the formation
of ammonia produced when the enzyme acts on adenosine. The
volume of 25 lL of the brain homogenates was used. The enzy-
matic reaction was started by addition of 500 lL of 21 mM adeno-
sine as substrate. The reaction was stopped by adding 1.5 mL of
106.2/0.16 mM phenol–nitroprusside to the reaction mixture,
which was immediately mixed with 1.5 mL of 125/11 mM alka-
line-hypochlorite (sodium hypochlorite). The ammonia released
reacted with alkaline-hypochlorite and phenol in the presence of
a catalyst-sodium nitroprusside to produce indophenol (a blue col-
or) and the concentration of ammonia was directly proportional to
the absorbance of indophenol read at 620 nm. Ammonium
sulphate of 75 lMwas used as ammonium standard. For the calcu-
lations of ADA activity, the protein concentration of the brain
homogenate was measured by the method of Bradford (1976) with
bovine serum albumin used as a standard. The value of ADA activ-
ity in the brain tissue was expressed as U/mg of protein.
2.8. Inﬂuence of deoxycoformycin on ADA activity of T. evansi
First, trypomastigotes of T. evansi in the blood of a rat (R2) were
separated with the aid of column diethylaminoethyl cellulose
(DEAE-C) according to the technique described by Tavares et al.
(2011). In pellet trypanosomes we evaluated ADA activity accord-
ing to the technique by Giusti and Galanti (1984), adapted and
published by Da Silva et al. (2011a–d). For the assays in vitro, the
deoxycoformycin was used at concentrations of 0, 25 pM, 1 nM
and 10 nM. The ADA activity in the trypanosomes was expressed
in U/L.
2.9. Statistic analysis
Data were submitted to one-way analysis of variance followed
by the Student’s t test (P < 0.05). Values were represented as
mean ± standard deviation. All samples were processed in
triplicate.
3. Results
3.1. Parasitemia
Animals in group D (positive control) showed increased parasi-
temia, being observed an average of 17 trypanosomes/ﬁeld on day
4 PI (subgroup D1) and 113 trypanosomes/ﬁeld on day 8 PI (sub-
group D2). Similar results were observed in mice in group F (trea-
ted with deoxycoformycin), i.e., 11 and 87 trypanosomes/ﬁeld onhemoglobin concentration, plasma total protein levels and total leukocytes) in mice
e and deoxycoformycin. Blood samples were analyzed on days 4 and 8 post-infection.
p C Group D Group E Group F Group G
(±2.6) 45.1a (±1.5) 47.0a (±1.5) 47.5a (±2.0) 45.0a (±2.3)
(±2.5) 38.0c (±1.0) 44.0ab (±1.5) 37.3c (±1.5) 49.5a (±3.5)
(±0.5) 8.4ª (±0.4) 8.1a (±0.3) 8.4ª (±0.3) 7.5ª (±0.4)
(±0.5) 6.7c (±0.2) 7.5bc (±0.5) 6.9c (±0.4) 8.8ª (±0.6)
(±0.7) 13.1a (±0.6) 13.2a (±0.2) 13.0a (±0.7) 12.3a (±0.8)
b (±0.7) 10.3c (±0.6) 12.1ab (±0.7) 10.8c (±0.7) 13.4a (±1.1)
(±0.2) 7.9a (±0.1) 7.8a (±0.2) 7.5ab (±0.3) 7.4abc (±0.2)
(±0.2) 7.4bc (±0.1) 8.0ab (±0.2) 8.4a (±0.7) 7.2c (±0.3)
(±2.1) 8.0a (±2.1) 4.8b (±2.3) 4.6b (±1.1) 3.6b (±1.3)
(±1.4) 8.9a (±1.0) 8.5a (±0.7) 10.9a (±3.5) 5.8ab (±1.4)
ce level of 5% in Student test. group A: uninfected and untreated animals, group B:
oxycoformycin, group D: infected and untreated, group E: infected and treated with
nfected and treated with combination 30-deoxyadenosine and deoxycoformycin.
Table 2
Mean and standard deviation of the activity of adenosine deaminase (ADA) in plasma
and brain of mice uninfected/infected with Trypanosoma evansi and untreated/treated
with 30-deoxyadenosine and deoxycoformycin. Blood samples were analyzed on days
4 and 8 post-infection.
Groups Mean and standard deviation of ADA activity in plasma (U/L) and
brain (U/mg of protein)
Day 4 post-infection Day 8 post-infection
Plasma Brain Plasma Brain
Group A 2.53 ± 0.31bc 14.52 ± 3.20a 2.75 ± 0.47b 13.68 ± 3.53a
Group B 3.35 ± 0.34ab 11.32 ± 1.21abc 3.13 ± 0.22b 10.93 ± 0.90a
Group C 1.40 ± 0.14de 8.36 ± 0.54cd 1.33 ± 0.08cd 1.63 ± 0.85b
Group D 2.03 ± 0.39cd 12.50 ± 1.48ab 1.70 ± 0.10c 12.52 ± 0.50a
Group E 3.71 ± 1.00a 11.06 ± 2.65abc 5.07 ± 0.7a 11.07 ± 0.97a
Group F 0.48 ± 0.22e 3.74 ± 0.87e 0.48 ± 0.10d 4.24 ± 0.10b
Group G 0.67 ± 0.23e 5.20 ± 0.84de 0.66 ± 0.30d 4.96 ± 0.62b
Mean followed by the same letter in the same column does not differ statistically
itself, the probability of 5% (P < 0.05) in Student test. group A: uninfected and
untreated animals, group B: uninfected and treated with 30-deoxyadenosine, group
C: uninfected and tretaed with deoxycoformycin, group D: infected and untreated,
group E: infected and treated with 30-deoxyadenosine, group F: infected and treated
with deoxycoformycin, and group G: infected and treated with combination 30-
deoxyadenosine and deoxycoformycin.
Fig. 1. Activity of adenosine deaminase (ADA) at a concentration of 0.6 mg mL1 of
pellet Trypanosoma evansi and tests with deoxycoformycin in different concentra-
tions. Different letters in the column determine that there is a signiﬁcant difference
between treatments (P < 0.05).
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presence of trypanosomes in blood smears on day 8 of the experi-
ment was not observed. After the treatment, no clinical sign show-
ing intoxication of animals was observed.
3.2. Hematological parameters
Animals in groups B and C (uninfected and treated) showed no
variation in the values of hematocrit, total erythrocytes, hemoglo-
bin, and total leukocytes when compared to group A (uninfected
and untreated). On the other hand, the levels of plasma total protein
decreased (P < 0.05) in animals treated with 30-deoxyadenosine
(group B) and deoxycoformycin (group C) when compared to group
A on day 4 PI (Table 1).
A decrease (P < 0.05) in the values of hematocrit, total erythro-
cytes, and hemoglobin concentration was observed in the infected
and untreated mice (group D) and infected and treated mice with
deoxycoformycin (group F) on day 8 PI (Table 1). The number of to-
tal leukocytes was signiﬁcantly (P < 0.05) increased in mice in-
fected and untreated (group D) on days 4 and 8 PI when
compared to the other groups, with the exception of group E and
group F which had a similar increase of leukocytes only on day 8
PI. The group G treated with the combination 30-deoxyadenosine
and deoxycoformycin did not show signiﬁcant variation (P > 0.05)
in hematologic parameter when compared to group A (Table 1).
3.3. ADA activity in plasma and brain
The results of ADA activity of animals in this experiment are
shown in Table 2. The animals in group B (uninfected and treated
with 30-deoxyadenosine) showed no signiﬁcant (P > 0.05) variation
in ADA activity in plasma and brain when compared to group A.
The treatment with deoxycoformycin in group C was able to signif-
icantly (P < 0.05) reduce the ADA activity in plasma and brain on
days 4 and 8 PI when compared to group A. Animals infected with
T. evansi and untreated (group D) showed reduction (P < 0.05) in
ADA activity in plasma only on day 8 PI compared to negative con-
trol. Animals in group E (infected and treated with 30-deoxyadeno-
sine) showed an increase in ADA activity in plasma on day 8 PI
(P < 0.05). In both groups F and G, the ADA activity in plasma and
brain of mice had a signiﬁcant (P < 0.05) reduction compared to
the negative control group.3.4. Effect of deoxycoformycin on the ADA activity of T. evansi
The concentration of proteins in the trypanosome pellet chosen
for the tests was 0.6 mg mL1, being this concentration used for the
tests with inhibitor. The results of ADA activity in the parasite and
deoxycoformycin effects on the activity of this enzyme are shown
in Fig. 1. A dose-dependent inhibition of ADA activity in the para-
site was observed when the inhibitor deoxycoformycin was used.
4. Discussion
In previous studies, our research group has found that the 30-
deoxyadenosine associated with ADA inhibitors such as EHNA
hydrochloride (Da Silva et al., 2011d) and deoxycoformycin (Dalla
Rosa et al., 2013) can be 42.5% and 100% effective in treating
infected mice with T. evansi, respectively. In both experiments
mentioned above, when only the ADA inhibitors were tested, no
curative effect was observed because parasitemia increased pro-
gressively. When 30-deoxyadenosine was used, the elimination of
the parasite from the blood for some time occurred, but with recur-
rent parasitemia. Similar results were observed in this study.
The present study was made due to histological lesions ob-
served in the liver and kidney of mice infected with T. evansi and
treated with the combination 30-deoxyadenosine and deoxycofor-
mycin (Dalla Rosa et al., 2013). Therefore, we aimed to check if
the treatment could inﬂuence the hematological parameters and
ADA activity in plasma and also in the brain, where it performs vi-
tal functions in mammals related to neuromodulation. However,
Dalla Rosa et al. (2013) found no histological lesions in the brain
of treated animals. The toxic effect of treatment was attributed
to the ADA inhibitor (deoxycoformycin) alone or associated with
30-deoxyadenosine in a study with dogs, being observed in the ani-
mal clinical signs of gastrointestinal toxicity, and bone marrow in-
jury causing lymphopenia, thrombocytopenia, and depletion of
hematopoietic cells (Rodman et al., 1997). However, apparently
the same did not occur in this study with the dose used.
Infections by T. evansi commonly cause anemia and leukocyto-
sis in domestic animals (Rodrigues et al., 2005; Wolkmer et al.,
2009). This ﬁnding was also visualized in mice in this study, which
showed the parasite circulating during the experiment (groups D
and F). The individual treatment with 30-deoxyadenosine and with
deoxycoformycin had no effect on hematology parameters, a fact
observed in healthy animals and treated with inhibitors of ADA
(groups B and C). In a ﬁrst moment of the study, a reduction in
the levels of plasma total protein (day 4 PI) was observed in healthy
mice treated with 30-deoxyadenosine and deoxycoformycin
(groups B and C) when compared to other groups. This ﬁnding
may suggest that drugs may tax and/or injure the liver, which is
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served in a previous study (Dalla Rosa et al., 2013). This did not oc-
cur when the same treatment was used in infected animals which
can be explained because the infection with T. evansi stimulates
the increase of protein as evidenced by Costa et al. (2010) in cats
experimentally infected with the parasite.
The ADA activity in plasma and brain of rodents infected with T.
evansi reduced signiﬁcantly (Da Silva et al., 2011a,b), which oc-
curred in this study in group D formed by infected and untreated
animals. Both drugs used in our experimental protocol caused at
some point alteration in ADA activity in plasma and/or brain. Inhi-
bition of ADA activity drew attention for groups that were treated
with deoxycoformycin which had a large decrease of ADA activity
in plasma and brain on days 4 and 8 PI. This result was expected on
day 4 PI, since the last dose of the drug was administered on day 3
PI. However, on day 8 PI, 5 days after the last dose of the drug, the
inhibition was not expected. This is because the ADA inhibitors
have a relatively short half-life (McConnell et al., 1978). According
to the researchers, the administration of deoxycoformycin in dogs,
rats and humans has rapid uptake and clearance of tissues, fol-
lowed by its rapid elimination through the urine, mainly in an
unmetabolized form (Borondy et al., 1977; McConnell et al.,
1978; Major et al., 1981). In rats, more than 90% of the adminis-
tered dose was recovered in the urine within 2 h after intraperito-
neal injection (McConnell et al., 1978), conﬁrming that the half life
of the drug is short. The same did not occur in our study. The ADA
activity was inhibited and remained inhibited compared to healthy
animals. Therefore, despite the fact the the curative treatment
shows efﬁcacy in the treatment for trypanosomosis, it can interfere
with other physiological functions that the ADA has participation
of the host.
ADA is widely distributed in tissues of vertebrate animals and
divided into two isoforms: ADA1 and ADA2. The deoxycoformycin
has the ability to inhibit both isoforms (Franco et al., 1986). As
mentioned in the introduction, this enzyme plays different roles
in mammalian and its deﬁciency may contribute to some disor-
ders. This reduction in ADA activity may have caused an increase
in the concentration of adenosine, which develops a neuroprotec-
tive and modulator role regarding the tissue damage and impaired
metabolism (Pearson et al., 2003). This may cause an imbalance in
the levels of nucleosides in the central nervous system (CNS), re-
duce deamination to inosine and thereby interfere the sequence
of enzymatic cascade. In addition to interfering with the CNS,
ADA deﬁciency could interfere with the immune response and
hematopoiesis, where this enzyme has important roles (Aran
et al., 1991; Xaus et al., 1999; Kumar and Sharma, 2009).
ADA inhibitors available in the pharmaceutical industry pre-
sents a number of drawbacks for clinical use such as problems in
their pharmacokinetics and/or severe toxic effects and high cost
(Cavalcante, 2010). The deoxycoformycin promotes intracellular
accumulation of adenosine nucleotides and deoxyadenosine,
blocking DNA synthesis by inhibiting ribonucleotide reductase,
and deoxyadenosine inactive to S-adenosyl homocysteine hydro-
lase, promoting the accumulation of S-adenosyl cysteine, which
is toxic to lymphocytes (Chabner et al., 2005). The results of this
study are worrisome because despite the fact that therapeutic pro-
tocol is effective in controlling trypanosomosis, it causes interfer-
ence in the purinergic system.
The activity of ADA was recently detected in T. evansi (Da Silva
et al., 2011c). Based on this information, this study suggests that
the deoxycoformycin is capable of inhibiting ADA present in para-
site. It is worth investigating whether this inhibition may lead to
parasite death and if this enzyme plays a vital role as it does in
mammals. In in vitro tests a reduction was visualized in the
number of parasites living deoxycoformycin only when adminis-
tered within the ﬁrst hour of experiment (Dalla Rosa et al.,2013). Therefore, we believe that the association of the ADA inhib-
itor 30-deoxyadenosine enhances the trypanocidal activity in vivo.
Based on these results, we conclude that the treatment with 30-
deoxyadenosine and deoxycoformycin in the doses used caused no
alterations in hematocrit, number of erythrocytes, and hemoglobin
concentration in mice infected with T. evansi. The number of leuko-
cyte differs between groups, but this variation seems to be associ-
ated with animals that had parasitemia by T. evansi. The plasma
total protein levels can be reduced as a consequence of this treat-
ment. The activity of ADA suffers strong inhibition in plasma and
brain of animals treated with deoxycoformycin. Therefore, the
therapeutic protocol inﬂuences the activity of ADA and this may
cause disturbances and side effects. As ADA and adenosine have
participation in the immune response, we conclude that this sys-
tem could be harmed by the treatment used in the current study.
Consequently, more research must be carried out before recom-
mending this treatment for trypanosomosis. Another conclusion
drawn from this experiment was that the deoxycoformycin is able
to inhibit the ADA activity in T. evansi, which may be related to the
mechanism of trypanocidal action of drug.Committee on ethics and animal welfare
The procedure was approved by the Animal Welfare Committee
of Universidade Federal de Santa Maria, number 026/2012.
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